文献速递糖尿病

司美格鲁肽治疗2型糖尿病的疗效与安全性:SUSTAIN试验的种族与民族亚组事后分析

Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该事后分析汇总SUSTAIN 1-5和7(3074例)及SUSTAIN 6(1648例)数据,比较司美格鲁肽在不同种族/民族亚组中的疗效与安全性。结果显示司美格鲁肽0.5和1.0 mg在各亚组均一致降低HbA1c和体重,安全性与总体人群相似,但亚洲亚组因不良事件提前停药的比例高于其他种族亚组。

要点

  • 司美格鲁肽0.5和1.0 mg在各raceth亚组均一致降低HbA1c和体重。
  • 各试验不良事件总体比例相似,最常见为胃肠道疾病。
  • 亚洲亚组因不良事件提前停药的比例高于其他种族亚组。

核心结论

  • 司美格鲁肽在2型糖尿病受试者中与一致且具临床意义的HbA1c和体重降低相关。
  • 疗效和安全性结局因种族或民族存在轻微差异。

研究设计与样本

  • SUSTAIN 1-5和7(汇总)及SUSTAIN 6试验的事后分析。
  • SUSTAIN 1-5和7共3074例受试者,SUSTAIN 6共1648例受试者。
  • 干预包括司美格鲁肽0.5或1.0 mg、安慰剂或活性对照药。

主要发现

  • 司美格鲁肽0.5和1.0 mg使HbA1c自基线分别降低1.0至1.5个百分点和1.3至2.0个百分点。
  • 司美格鲁肽0.5和1.0 mg使体重分别降低2.3至4.7 kg和3.6至6.1 kg。
  • 观察到血压和血脂谱的轻微变化。
  • 各试验不良事件报告比例相似,最常见为胃肠道疾病。
  • 亚洲亚组因不良事件提前停药的比例高于其他种族亚组。

临床怎么用

  • 在2型糖尿病不同种族/民族患者中,司美格鲁肽的降糖和减重疗效总体一致。
  • 对亚洲患者需关注不良事件导致的提前停药风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Variations in the prevalence and etiology of type 2 diabetes (T2D) across race and ethnicity may affect treatment responses. Semaglutide is a glucagon-like peptide-1 analog approved for once-weekly, subcutaneous treatment of T2D. OBJECTIVE: To compare semaglutide efficacy and safety in race and ethnicity subgroups across the SUSTAIN trials. DESIGN: Post hoc analysis of data from phase 3 randomized SUSTAIN 1-5 and 7 (pooled), and SUSTAIN 6 trials. PARTICIPANTS: 3074 subjects (SUSTAIN 1-5 and 7) and 1648 subjects (SUSTAIN 6). INTERVENTIONS: Semaglutide 0.5 or 1.0 mg, placebo, or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine 100IU/ml and dulaglutide 0.75 or 1.5 mg). MAIN OUTCOME MEASURES: Change in hemoglobin A1C (HbA1c) and body weight from baseline to weeks 30, 40 and 104, and other efficacy and safety endpoints. RESULTS: HbA1c was reduced from baseline by 1.0 to 1.5 percentage points and 1.3 to 2.0 percentage points, and body weight was reduced by 2.3 to 4.7 kg and 3.6 to 6.1 kg with semaglutide 0.5 and 1.0 mg, respectively, across race and ethnicity subgroups. Minor changes in blood pressure and lipid profiles were observed. Adverse events (AEs) were reported in similar proportions of subjects across trials. More Asian versus other race subgroups discontinued treatment prematurely due to AEs. The most commonly reported AEs were gastrointestinal disorders. CONCLUSIONS: In this SUSTAIN trials post hoc analysis, semaglutide was associated with consistent and clinically relevant reductions in HbA1c and body weight in subjects with T2D, with minor variations in efficacy and safety outcomes associated with race or ethnicity.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. DeSouza C, Cariou B, Garg S, et al. Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials. J Clin Endocrinol Metab. 2020. PMID: 31769496. doi:10.1210/clinem/dgz072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。